Try our Advanced Search for more refined results
Life Sciences
-
January 16, 2026
NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.
-
January 16, 2026
Acadia Investors Get Initial OK For $179M Settlement
Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.
-
January 16, 2026
Pomerantz To Lead Biohaven Investors' FDA Approval Suit
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
-
January 16, 2026
Taxation With Representation: Stibbe, A&O Shearman, Latham
In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.
-
January 16, 2026
J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit
A New Jersey federal judge largely shot down Johnson & Johnson's bid to scrap a former company data privacy attorney's racial and gender discrimination suit and rejected its bid to sanction her over the case.
-
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
The U.S. Supreme Court agreed Friday to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent case over its "skinny label" on a generic heart drug, after the Trump administration urged the court to take the case.
-
January 16, 2026
Bioness $110M Sale Suit Heads to $8.9M Deal
A Delaware Chancery Court class action challenging the $110 million sale of medical device maker Bioness Inc. to Bioventus Inc. is reaching a resolution through an $8.9 million proposed settlement, capping years of litigation over whether the deal was engineered to favor the company's controlling creditor at the expense of minority stockholders.
-
January 15, 2026
SEC Says Healthcare Exec Misspent $10.6M In Investor Funds
The U.S. Securities and Exchange Commission on Thursday accused a healthcare company CEO of misappropriating over $10 million from investors by falsely claiming the funds would be used to develop cancer screening and treatment technology when in fact they were spent on credit card debt, luxury vehicles and strip club visits.
-
January 15, 2026
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading
New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.
-
January 15, 2026
Trial 'No Longer Warranted' After Judge's Stelara Reversal
The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia federal judge reversed course and nixed key claims he had previously teed up for trial.
-
January 15, 2026
Simpson Thacher Guides New Mountain's $1.2B Fund Close
New Mountain Capital LLC, guided by Simpson Thacher & Bartlett LLP, has closed its second noncontrol private equity fund with $1.2 billion raised, aiming to use the funds to target companies in industries such as healthcare technology and life sciences, the alternative investment firm announced on Thursday.
-
January 15, 2026
Chancery Tosses Vividion IP Suit Over $2B Bayer Deal
The Delaware Chancery Court on Thursday dismissed a biotech investor's suit accusing the co-founder of Vividion Therapeutics Inc. and others of diverting valuable intellectual property ahead of the company's $2 billion sale to Bayer Corp., finding the alleged misconduct could not have affected the merger price or process under Delaware law.
-
January 15, 2026
CVS Ducks Antitrust But Not Biz Interference Claim At 5th Circ.
A Fifth Circuit panel has largely sided with CVS Pharmacy and its Caremark affiliate by preserving a district court's dismissal of federal antitrust claims over a Mississippi pharmacy's rejection from participating in the pharmacy benefit manager's network, although the judges did revive state law claims.
-
January 15, 2026
Rite Aid Trusts Can Access Health Data To Pursue Tort Claims
A New Jersey bankruptcy judge said Thursday he will allow trusts set up under Rite Aid's first Chapter 11 plan to examine personal health data to support their effort to litigate tort and insurance claims, overruling the new Rite Aid debtor's objection.
-
January 15, 2026
Crowell Lands Buchalter Practice Group Co-Chair In Calif.
Crowell & Moring LLP announced Thursday that it has added the former co-chair of Buchalter PC's white collar and government investigations practice to bolster its capacity to handle healthcare fraud and other cases.
-
January 15, 2026
White & Case Adds Life Sciences Team From A&O Shearman
White & Case LLP announced the addition of four life sciences intellectual property litigators from Allen Overy Shearman Sterling on Thursday, marking its latest IP-focused hires from the London-based firm.
-
January 15, 2026
Carlyle Among Bidders For Lukoil Assets, Plus More Rumors
Private equity giant Carlyle is among a group of bidders reportedly looking to grab hold of $22 billion worth of Russia's Lukoil assets; Canadian oil and gas company Canadian Natural Resources is looking to acquire Tourmaline Oil Corp.'s $1 billion portfolio of natural gas properties; and Nvidia rival Cerebras eyes a $22 billion valuation after a planned $1 billion funding round.
-
January 15, 2026
3 Firms Advise On Boston Scientific's $14.5B Penumbra Deal
Allen Overy Shearman Sterling and Arnold & Porter are advising Boston Scientific Corp. on an agreement announced Thursday for the global medical technology company to purchase Davis Polk-advised Penumbra Inc. at a $14.5 billion enterprise value.
-
January 14, 2026
Dover Launches RICO Suit Over Skyrocketing Insulin Prices
Manufacturing conglomerate Dover Corp. hit insulin manufacturers including Eli Lilly and Novo Nordisk and several pharmacy benefit managers with civil racketeering claims in Illinois federal court, accusing them of participating in an illegal scheme that allowed prices to rise dramatically in exchange for preferential treatment on the benefit managers' formularies.
-
January 14, 2026
Pharmacy Wields Antitrust Law In Challenge To GLP-1 Giants
Eli Lilly & Co. and Novo Nordisk are using their dominant positions in the market for weight loss and diabetes medications to squash potential competitors, including through unlawful exclusivity agreements with telehealth providers, a compounding pharmacy alleged Wednesday in what it calls a landmark antitrust lawsuit.
-
January 14, 2026
6th Circ. Skips Rethink, But Still Spars Over Indirect Buyer Bar
A decision by the full Sixth Circuit not to rehear a lawsuit over an alleged allergy testing and treatment provider boycott has turned into an internal dustup about the limits of who can seek damages under federal antitrust law, with one judge calling for U.S. Supreme Court intervention.
-
January 14, 2026
Exasperated Judge Won't Expand Opioid Film Injunction
BioDelivery Sciences International needed to pursue a contempt order, not an enforcement action, when alleging a 2022 injunction blocking Alvogen's generic version of its Belbuca opioid film should be applied to a new generic application, a Delaware federal judge held in a case where he was already "frustrated (and exhausted)."
-
January 14, 2026
NJ Judge Orders Mediation In Merck-Cencora Indemnity Fight
Cencora Inc. can't derail a Merck third-party complaint arguing a prior settlement between the parties requires the drug wholesaler to indemnify Merck in antitrust litigation by Humana, a New Jersey federal court ruled Wednesday, ordering the parties to go to mediation over the dispute.
-
January 14, 2026
Biotech Co. CytoDyn In Talks To End Investor Class Action
A federal judge has given the green light for biotech company CytoDyn Inc. and its former leadership to move forward with a potential settlement of a proposed class action that accused the company of misleading shareholders over the alleged approval of its COVID-19 and HIV drug.
-
January 14, 2026
Wholesaler Admits To $2.5M Opioid Diversion Scheme
A Miami-based pharmaceutical wholesaler has signed on to a two-year deferred prosecution agreement with federal prosecutors over a charge that it knowingly diverted opioids to "pill mill" pharmacies, bringing in more than $2.5 million.
Expert Analysis
-
Rare Del. Oversight Ruling Sends Governance Wake-Up Call
An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.
-
How Hyperlinks Are Changing E-Discovery Responsibilities
A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.
-
Pharma Copay Programs Raise Complex Economic Questions
The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.
-
State False Claims Acts Can Help Curb Opioid Fund Fraud
State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.
-
Beaming Up Lessons From William Shatner's Failed Patent Bid
In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.
-
The Pros And Cons Of Levying Value-Based Fees On Patents
The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.
-
Series
Writing Musicals Makes Me A Better Lawyer
My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.
-
Between The Lines Of EPO's Adoption Of Color Drawings
The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.
-
What Prop 65 Ruling Means For Cosmetics, Personal Care Biz
A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.
-
Series
Adapting To Private Practice: From Va. AUSA To Mid-Law
Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.
-
2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls
Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.
-
Rebutting Price Impact In Securities Class Actions
Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.
-
7 Document Review Concepts New Attorneys Need To Know
For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.
-
Ruling On Labor Peace Law Marks Shift For Cannabis Cos.
Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.
-
Fed. Circ. Rulings Refine Patent Claim Construction Standards
Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.